Search Results

Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is a Bronze Sponsor of the 10th Annual Elite Ped-GI Congress, which takes place May 2-4, 2024 in Abu Dhabi in the United Arab Emirates (UAE).

In an effort to shed light on the diverse and profound challenges faced by individuals living with a diagnosis or a history of cancer, Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced they were proud to provide fiscal support for More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer.

Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that it will exhibit at the Annual Association of Nurses in AIDS Care (ANAC) Conference.

Napo Pharmaceuticals, a Jaguar Health, Inc. family company, announced that a Multinational Association of Supportive Care in Cancer webinar titled “GI Toxicities from Cancer Therapies - Prevention and Management,” taking place Monday, January 29, 2024 from 11:30 AM to 12:30 PM Eastern Standard Time, was made possible by an unrestricted educational grant from Napo.

Napo Pharmaceuticals Inc. (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) company, today announced the activation by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for a new crofelemer powder for oral solution formulation for the treatment of microvillus inclusion disease (MVID), an ultra-rare congenital diarrheal disorder (CDD).

Napo Pharmaceuticals, Inc. (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the results of a Napo-sponsored survey of 15 US neurologists who treat patients with amyotrophic lateral sclerosis (ALS), and the results of a corresponding Napo-sponsored survey of 15 US individuals who are either ALS patients or caregivers of an ALS patient.

Napo Pharmaceuticals today announced that the abstract for More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer.

Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”) today announced that Jaguar family companies Napo Pharmaceuticals (“Napo”) and Napo Therapeutics have submitted a Clinical Trial Application (CTA) to the Italian and German health authorities to initiate a phase 2 clinical trial of Jaguar’s novel plant-based prescription drug crofelemer for treatment of short bowel syndrome (SBS) with intestinal failure in adults.

Napo Pharmaceuticals Inc., a Jaguar Health, Inc. (NASDAQ:JAGX) company, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a new crofelemer powder for oral solution formulation for the treatment of microvillus inclusion disease (MVID).

Napo Pharmaceuticals (Napo), a Jaguar Health (NASDAQ:JAGX) (Jaguar) family company, today announced that it has submitted a grant application to the National Institute of Allergy and Infectious Diseases (NIAID) for funding to support Napo’s Phase I study of NP-300.